Berinert FDA Approval History
Last updated by Judith Stewart, BPharm on Feb 25, 2021.
FDA Approved: Yes (First approved October 9, 2009)
Brand name: Berinert
Generic name: C1 esterase inhibitor (human)
Dosage form: Injection
Company: CSL Behring
Treatment for: Hereditary Angioedema
Berinert (C1-esterase inhibitor (human)) is a plasma derived C1 esterase inhibitor indicated for the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) in adult and pediatric patients.
Development timeline for Berinert
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.